Page last updated: 2024-11-06

cromakalim

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cromakalim is a potassium channel opener that has been studied for its potential therapeutic effects in a variety of conditions, including hypertension, diabetes, and asthma. It is a synthetic compound that was first developed in the 1980s. Cromakalim works by activating ATP-sensitive potassium channels, which are found in the smooth muscle of blood vessels, the heart, and the airways. This activation leads to hyperpolarization of the cell membrane, which inhibits the release of calcium and relaxes smooth muscle. The relaxation of smooth muscle in blood vessels leads to vasodilation and a reduction in blood pressure. In the heart, it can slow heart rate and reduce the force of contraction. In the airways, it can relax the smooth muscle and improve airflow. However, cromakalim has been shown to have significant side effects, including hypotension, dizziness, and nausea. As a result, it has not been widely used clinically. Research on cromakalim is ongoing, and it is possible that new formulations or delivery methods may be developed in the future that could minimize these side effects.'

Cromakalim: A potassium-channel opening vasodilator that has been investigated in the management of hypertension. It has also been tried in patients with asthma. (Martindale, The Extra Pharmacopoeia, 30th ed, p352) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71191
CHEMBL ID11684
SCHEMBL ID12833
MeSH IDM0029396
PubMed CID443423
CHEMBL ID49035
CHEBI ID3921
SCHEMBL ID3312760
MeSH IDM0029396

Synonyms (62)

Synonym
racemic-3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
(3r,4s)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)chromane-6-carbonitrile
3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile;(cromakalim)
(3r,4r)-3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
(cromakalim)3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
bdbm50044253
(r)-3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
(3r,4s)-3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2h-chromene-6-carbonitrile
(s)-3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
(3s,4r)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2h-chromene-6-carbonitrile
tocris-1378
NCGC00025132-01
NCGC00025132-02
tocris-1377
cromakalim
94470-67-4
cromakalin
NCGC00168470-01
CHEMBL11684 ,
(3r,4s)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydrochromene-6-carbonitrile
(3s,4r)-3-hydroxy-2,2-dimethyl-4-(2-oxo-pyrrolidin-1-yl)-chroman-6-carbonitrile
94535-51-0
(+/-)-cromakalim
SCHEMBL12833
Q3698301
DTXSID001017959
2h-1-benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-, (3r,4s)-
MS-24088
DTXSID301317350
(3r,4s)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)chroman-6-carbonitrile
(3r,4s)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2h-1-benzopyran-6-carbonitrile
AKOS040744858
HMS3267D04
BRD-A76093993-001-01-8
cromakalim, (3r-trans)-isomer
brl 38226
3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)chroman-6-carbonitrile
gtpl2413
3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydrochromene-6-carbonitrile
nsc_93504
bdbm86251
cromakalim (-)
cas_94535-50-9
CHEMBL49035
chebi:3921 ,
(+)-cromakalim
(3r-trans)-cromakalim
2h-1-benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-, (3r-trans)-
FT-0624100
FT-0630985
HMS3369L14
2h-1-benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-, (3r,4s)-rel-
SCHEMBL3312760
2h-benzopyran-6-carbonitrile, 3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-
TVZCRIROJQEVOT-UHFFFAOYSA-N
3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-chromanecarbonitrile #
AKOS030255268
(-)-cromakalim;brl 38227
F82193
DTXSID80861136
3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2h-1-benzopyran-6-carbonitrile

Research Excerpts

Overview

Cromakalim (BRL 34915) is a potassium channel opener with therapeutic potential as a bronchodilator in asthma. It is a benzopyran derivative which relaxes smooth muscle, probably by opening membrane potassium channels. CromakAlim is an effective spasmolytic against a number of vasoconstrictors in the dog coronary artery.

ExcerptReferenceRelevance
"Levcromakalim is a vasorelaxant used in the management of hypertension in diabetes mellitus. "( Evaluation of the potassium channel activator levcromakalim (BRL38227) on the lipid profile, electrolytes and blood glucose levels of streptozotocin-diabetic rats.
Omogbai, EK; Owolabi, OJ, 2013
)
1.27
"Cromakalim is a member of the new antihypertensive drug family possessing an action that involves an increased K efflux in vascular and cardiac muscle. "( Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Das, DK; Engelman, RM; Szerdahelyi, P; Tosaki, A, 1993
)
1.73
"Cromakalim is a K(+) channel opener that causes smooth muscle relaxation by activating ATP-sensitive K(+) (K(ATP)) channels and producing membrane hyperpolarization. "( Cromakalim: embryonic effects and reduction of tolbutamide-induced dysmorphogenesis in vitro.
Smoak, IW, 1999
)
3.19
"Cromakalim (BRL 34915) is a potassium channel opener with therapeutic potential as a bronchodilator in asthma. "( The relaxant effects of cromakalim (BRL 34915) on human isolated airway smooth muscle.
Cortijo, J; Morcillo, E; Paris, F; Pedrós, C; Perpiñá, M; Sarriá, B, 1992
)
2.03
"Cromakalim is a benzopyran derivative which relaxes smooth muscle, probably by opening membrane potassium channels. "( The effect of cromakalim on the normal and hyper-reflexic human detrusor muscle.
Mundy, AR; Nurse, DE; Restorick, JM, 1991
)
2.08
"Cromakalim is an effective spasmolytic against a number of vasoconstrictors in the dog coronary artery."( Spasmolytic effect of cromakalim in dog coronary artery in vitro.
Angus, JA; Keily, SG; McPherson, GA, 1991
)
1.32

Effects

Cromakalim has a vasodilatory effect on the umbilical artery like magnesium sulphate and nifedipine, and serves as an antihypertensive potential that might be used in the treatment of preeclampsia. It has been shown to have anti-ischemic properties, but it also produces profound hypotension upon systemic administration.

ExcerptReferenceRelevance
"Levcromakalim has a vasodilatory effect on the umbilical artery like magnesium sulphate and nifedipine, and serves as an antihypertensive potential that might be used in the treatment of preeclampsia. "( Vasorelaxant effect of levcromakalim on isolated umbilical arteries of preeclamptic women.
Danisman, N; Polat, B; Tufan, H, 2007
)
1.26
"Levcromakalim has a vasodilatory effect on the umbilical artery like magnesium sulphate and nifedipine, and serves as an antihypertensive potential that might be used in the treatment of preeclampsia. "( Vasorelaxant effect of levcromakalim on isolated umbilical arteries of preeclamptic women.
Danisman, N; Polat, B; Tufan, H, 2007
)
1.26
"Levcromakalim (1 microM) has no additional effect on the transient contraction induced by PGF2 alpha in Ca(++)-free solution in PRV and PA.(ABSTRACT TRUNCATED AT 250 WORDS)"( Effect of levcromakalim on hypoxia-, KCl- and prostaglandin F2 alpha-induced contractions in isolated rat pulmonary artery.
Morice, AH; Zhang, F, 1994
)
1.17
"Cromakalim alone has been shown to be protective, however when combined with glibenclamide necrosis amounted to 35.1 +/- 3.8% of the risk region (p = NS vs."( Cardioprotection with U-89232 is not reversible with glibenclamide: evidence of a novel anti-ischemic agent derived from cromakalim.
Moore, TL; Shebuski, RJ; Toombs, CF, 1994
)
1.22
"(-)-Cromakalim has no effect on the earliest events associated with exposure to glutamate."( The potassium channel opener (-)-cromakalim prevents glutamate-induced cell death in hippocampal neurons.
De Weille, JR; Lauritzen, I; Lazdunski, M, 1997
)
1.06
"Cromakalim has been shown to have anti-ischemic properties, but it also produces profound hypotension upon systemic administration. "( Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo.
Gadwood, RC; Groppi, VE; Lee, KS; Norman, NR; Shebuski, RJ; Toombs, CF, 1992
)
1.96
"Cromakalim has been shown to inhibit naphazoline-induced contractions and spontaneous activity induced by exposure to naphazoline in the rat isolated vas deferens. "( Inhibition by glibenclamide of the effects of cromakalim on responses of rat vas deferens to naphazoline.
Barbieri, A; Grana, E; Zonta, F, 1991
)
1.98

Actions

Cromakalim was able to inhibit uterine contractions during oxytocin infusion in both corn oil- and oestradiol-treated rats. The cromakAlim-induced increase in 86Rb efflux was also inhibited by glibenclamide.

ExcerptReferenceRelevance
"The cromakalim-induced increase in 42K+ efflux was enhanced 3.5-fold in the presence of KCl (20 mM) plus (+)-cis-diltiazem (3 microM), a property shared by RP 49356."( Cromakalim- and RP 49356-induced 42K+ and 86Rb+ efflux in rat myometrium.
Hollingsworth, M; Piper, IT, 1995
)
2.21
"Levcromakalim did not suppress but rather enhanced ouabain-induced VT by decreasing the cycle length slightly from 315 +/- 35 to 290 +/- 35 msec (P < 0.05)."( Mechanism-specific antiarrhythmic effects of the potassium channel activator levcromakalim against repolarization-dependent tachycardias.
De Groot, SH; Gorgels, AP; Leunissen, JD; Lipcsei, GC; Vos, MA; Wellens, HJ, 1994
)
1.03
"Cromakalim was able to produce an additional relaxation response in the presence of a maximal relaxation induced by salbutamol and theophylline."( [Effects of the potassium channel activator cromakalim on human isolated bronchial smooth muscle].
Liu, J; Luo, Y; Zhou, L, 1995
)
1.27
"Cromakalim was able to inhibit in a concentration-dependent manner the first purinergic phase (pD2 = 5.90 +/- 0.11), leaving practically unaffected the second, adrenergic phase."( Cromakalim blocks the purinergic response evoked in rat vas deferens by single-pulse electrical stimulation.
Bianchi, L; Boselli, C; Grana, E, 1997
)
2.46
"Cromakalim was able to inhibit only partially the response to carbachol and profoundly affected the response to exogenous ATP."( Effect of cromakalim on the purinergic and cholinergic transmission in the rat detrusor muscle.
Bianchi, L; Boselli, C; Grana, E, 1997
)
1.42
"Cromakalim did not increase uterine cyclic AMP concentrations, suggesting that stimulation of adenylate cyclase is not significant in the uterine relaxant action of cromakalim."( One way cross tolerance between cromakalim and salbutamol in the uterus of the rat in vivo.
Downing, SJ; Hollingsworth, M, 1992
)
1.29
"Cromakalim appears to inhibit 21-hydroxylase activity in the biosynthetic pathway and may also affect 3 beta-hydroxysteroid dehydrogenase activity."( Membrane permeability to K+ and the control of aldosterone synthesis: effects of valinomycin and cromakalim in bovine adrenocortical cells.
Fraser, R; Kenyon, CJ; Shepherd, RM, 1992
)
1.22
"Cromakalim did not inhibit insulin release at these concentrations."( Differential effects of cromakalim on pancreatic vascular resistance and insulin secretion in vitro.
Hillaire-Buys, D; Loubatières-Mariani, MM; Mir, AK; Petit, P, 1992
)
1.31
"Cromakalim was able to inhibit uterine contractions during oxytocin infusion in both corn oil- and oestradiol-treated rats, uterine sensitivity to cromakalim being similar in the absence and presence of oxytocin for both hormone treatment groups."( Interaction between myometrial relaxants and oxytocin: a comparison between relaxin, cromakalim and salbutamol.
Downing, SJ; Hollingsworth, M, 1992
)
1.23
"The cromakalim-induced increase in 86Rb efflux was also inhibited by glibenclamide."( The diverse effects of cromakalim on tension and 86Rb efflux in canine arterial smooth muscle.
Asano, M; Masuzawa, K; Matsuda, T, 1991
)
1.07
"4. Cromakalim can produce long-lasting inhibition of uterine contractions in the rat after bolus i.v."( Tolerance to cromakalim in the rat uterus in vivo.
Downing, SJ; Hollingsworth, M; Miller, M, 1989
)
1.16

Treatment

Cromakalim has a protective effect against IR-induced testicular damage via activating K(ATP) channels. Treatment with cromkalim A, a nonspecific K(+) channel activator, also induced ERK1/2 dephosphorylation.

ExcerptReferenceRelevance
"Levcromakalim treatment significantly reduced total cholesterol, low-density lipoprotein (LDL), and triglyceride levels in diabetic rats (all P < 0.05 compared with untreated diabetic rats). "( Evaluation of the potassium channel activator levcromakalim (BRL38227) on the lipid profile, electrolytes and blood glucose levels of streptozotocin-diabetic rats.
Omogbai, EK; Owolabi, OJ, 2013
)
1.27
"Cromakalim treatment also prevented alloxan-induced hypercholesterolemia and hypertriglyceridaemia."( Effects of chronic treatment with cromakalim and glibenclamide in alloxan-induced diabetic rats.
Goyal, RK; Kulkarni, JS; Metha, AA; Santani, DD, 2002
)
1.32
"Cromakalim pretreatment had no significant effect on poststorage systolic or diastolic function of hearts explanted from brain-dead or sham-operation rabbits."( Pretreatment with a potassium-channel opener before prolonged cardiac storage: an evaluation in an experimental brain death model.
Astier, A; Baufreton, C; Bertrand, S; Fernandez, C; Garnier, JP; Kirsch, M; Loisance, D, 1999
)
1.02
"Cromakalim pretreatment (both when given throughout the experiment and when not present in the reperfusion buffer) resulted in significant improvements in the reperfusion function."( The protective effects of cromakalim and pinacidil on reperfusion function and infarct size in isolated perfused rat hearts and anesthetized dogs.
Dzwonczyk, S; Grover, GJ; Parham, CS; Sleph, PG, 1990
)
1.3
"Treatment with cromakalim ameliorated these parameters compared to the non-treated IR group."( The role of K ATP channels on ischemia-reperfusion injury in the rat testis.
Dimitriadis, F; Kinoshita, Y; Kitatani, K; Saito, M; Satoh, K; Shomori, K; Takenaka, A; Tsounapi, P, 2012
)
0.72
"Treatment with cromakalim has a protective effect against IR-induced testicular damage via activating K(ATP) channels. "( The role of K ATP channels on ischemia-reperfusion injury in the rat testis.
Dimitriadis, F; Kinoshita, Y; Kitatani, K; Saito, M; Satoh, K; Shomori, K; Takenaka, A; Tsounapi, P, 2012
)
0.73
"Treatment with cromakalim-prevented hypertension and bradycardia, but not the hyperglycemia or hypoinsulinaemia."( Effects of chronic treatment with cromakalim and glibenclamide in alloxan-induced diabetic rats.
Goyal, RK; Kulkarni, JS; Metha, AA; Santani, DD, 2002
)
0.93
"Pretreatment with cromakalim, an opener of K(ATP) channels, occluded the hypoxia-induced hyperpolarization."( Effect of acute hypoxia on ATP-sensitive potassium currents in substantia gelatinosa neurons of juvenile rats.
Jung, SJ; Kim, J; Kwak, J; Lim, W; Park, YK; Yoo, JE, 2003
)
0.64
"Treatment with cromakalim A, a nonspecific K(+) channel activator, also induced ERK1/2 dephosphorylation, while blockade of Kv.1.2 K(+) channels (AM92016 hydrochloride) prevented NO-induced ERK1/2 dephosphorylation."( Role of SHP-1, Kv.1.2, and cGMP in nitric oxide-induced ERK1/2 MAP kinase dephosphorylation in rat vascular smooth muscle cells.
Belmadani, S; Lucchesi, PA; Matrougui, K; Palen, DI, 2005
)
0.67
"Pretreatment with cromakalim (CROM) (1 mg/kg, intraperitoneally [i.p.]) antagonized the anti-immobility effect of the mixed noradrenaline (NA)/5-hydroxytryptamine (5-HT) reuptake inhibitors imipramine and amitriptyline (P < 0.05)."( The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice.
Bourin, M; Pinot, P; Redrobe, JP, 1996
)
0.87
"Pretreatment with cromakalim (50-500 micrograms kg-1, p.o.) resulted in a significant reduction in the incidence of gastric and duodenal ulceration in each model."( Anti-ulcer activity of cromakalim (BRL 34915), a potassium-channel opener, against experimentally induced gastric and duodenal ulcers in rats and guinea-pigs.
Goswami, S; Jain, S; Santani, D, 1997
)
0.93
"Pretreatment with cromakalim also decreased lactate excretion in the coronary effluent."( Effect of cromakalim on ischemic and reperfused immature heart: experiments with isolated neonatal New Zealand white rabbit hearts.
Katoh, I; Kitagawa, T; Masuda, Y; Shimoe, Y; Yoshizumi, M, 1996
)
1.02
"Pre-treatment with cromakalim delayed the time to ischemic contracture (19.3 +/- 1.5 min v 15.3 +/- 0.6 for control, P < 0.05) and significantly improved recovery of function at 45 min reperfusion (84 +/- 11% pre-ischemic rate pressure product (RPP) v 38 +/- 5 for control, P < 0.05)."( Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Deslauriers, R; Docherty, JC; Gunter, HE; Kuzio, B; Shoemaker, L; Yang, L, 1997
)
1.01
"Pretreatment with cromakalim affords additional protection to that provided by cardioplegic arrest and prolonged cold storage using an extracellular solution. "( Preconditioning with cromakalim improves long-term myocardial preservation for heart transplantation.
Astier, A; Baufreton, C; Brunet, S; Fernandez, C; Kirsch, M; Loisance, DY; Pasteau, F, 1998
)
0.95
"Treatment with cromakalim dose-dependently attenuated SAH-induced constriction."( Delayed administration of the K+ channel activator cromakalim attenuates cerebral vasospasm after experimental subarachnoid hemorrhage.
Chen, EF; Howng, SL; Kassell, NF; Kwan, AL; Lee, KS; Lin, CL; Wu, CS, 2000
)
0.9
"Treatment with cromakalim produced profound hypotension (greater than 30% decrease in mean arterial pressure), whereas U-89,232 had no such hemodynamic effect."( Limitation of myocardial injury with the potassium channel opener cromakalim and the nonvasoactive analog U-89,232: vascular vs. cardiac actions in vitro and in vivo.
Gadwood, RC; Groppi, VE; Lee, KS; Norman, NR; Shebuski, RJ; Toombs, CF, 1992
)
0.86
"treatment with cromakalim and nicorandil did not result in significant changes in peripheral hemodynamic status, i.v."( Nicorandil improves postischemic contractile function independently of direct myocardial effects.
Grover, GJ; Parham, CS; Sleph, PG, 1990
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" In conclusion, isolated mesenteric arteries from obese Zucker rats do not show relevant structural changes, and the pharmacodynamic behaviour of such vessels appears to be the same as that of control preparations."( Pharmacodynamic behaviour of isolated resistance vessels obtained from hypertensive-diabetic rats.
Kam, KL; Pfaffendorf, M; van Zwieten, PA, 1996
)
0.29
" To evaluate the pharmacokinetic and safety profile of CKLP1 and its parent compound levcromakalim, Dutch-belted pigmented rabbits were treated intravenously (0."( Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbits.
Bahler, CK; Dosa, PI; Fautsch, MP; Hann, CR; Holman, BH; Kudgus, RA; Reid, JM; Rinkoski, TA; Roy Chowdhury, U, 2020
)
0.78

Bioavailability

ExcerptReferenceRelevance
" With its good oral bioavailability (47%) and plasma elimination half-life (3 h) in rats, compound 3 offers an excellent candidate to investigate the role of residual vasorelaxant potency of 2 toward its cardioprotective activity in vivo."( Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.
Ahmed, SZ; Atwal, KS; Baird, AJ; Ding, CZ; Dzwonczyk, S; Ferrara, FN; Grover, GJ; Humphreys, WG; McLaughlin, LG; Normandin, DE; Rovnyak, GC; Santafianos, D; Sleph, PG; Traeger, SC, 1997
)
0.3

Dosage Studied

The effects of tramadol (racemic, R(-) and S(+): 10(-6), 10(-5), 5 x 10 (-5) M), and glibenclamide on the levcromakalim dose-response curve were assessed in aortic rings that had been pre-contracted with phenylephrine. Diazoxide (2 microg/mouse) shifted morphine's dose- response curve 47-fold, while levcrukalim (0.1 nM) produced concentration-dependent inhibitory effect on spontaneity.

ExcerptRelevanceReference
"05) without affecting exogenously applied acetylcholine dose-response curves."( Role of K+ channels in the modulation of cholinergic neural responses in guinea-pig and human airways.
Barnes, PJ; Belvisi, MG; Miura, M; Stretton, CD; Yacoub, MH, 1992
)
0.28
" Phentolamine, antazoline, tolazoline, and midaglizole also shifted the dose-response curve for nicorandil to the right in the dose range of 1-100 microM."( Effects of imidazoline-related compounds on the mechanical response to nicorandil in the rat portal vein.
Ichihara, K; Nagasaka, M; Okumura, K, 1992
)
0.28
"1 mg/kg) occurred during an 8-week repeated daily dosing to RHD and plasma renin activity, and aldosterone levels were not elevated during this period."( Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
Aoki, K; Fukunari, A; Katoh, A; Nakajima, T; Setoguchi, M; Shinagawa, K; Shinohara, T; Tahara, T; Yamanaka, T; Yaoka, O, 1992
)
0.28
" Cells were held at 0 mV and BRL 38227 was added cumulatively to construct a dose-response relationship."( Effects of BRL 38227 on potassium currents in smooth muscle cells isolated from rabbit portal vein and human mesenteric artery.
Aaronson, PI; Russell, SN; Smirnov, SV, 1992
)
0.28
" In a repeat, once daily dosing experiment no tolerance was observed to the antihypertensive effect of Ro 31-6930 over a 22-day period."( Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.
Burden, DT; Burke, YM; Cowlrick, IS; Paciorek, PM; Perkins, RS; Taylor, JC; Waterfall, JF, 1990
)
0.28
"1 and 1 microM), with a three-fold and eight-fold shift to the right of the dose-response curve, respectively."( The action of a potassium channel activator, BRL 38227 (lemakalim), on human airway smooth muscle.
Alouan, LA; Armour, CL; Barnes, PJ; Black, JL; Johnson, PR, 1990
)
0.28
" Dose-response curves for the increase in coronary blood flow produced by nicorandil or cromakalim were shifted to the right in a parallel manner and to similar extents by glibenclamide given intravenously to support dogs."( Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism.
Satoh, K; Taira, N; Yoneyama, F, 1990
)
0.5
" The antihypertensive response to BRL 34915 in these models is reproducible on repeat once daily dosing without rebound hypertension on cessation of dosing."( BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models.
Buckingham, RE; Clapham, JC; Hamilton, TC; Longman, SD; Norton, J; Poyser, RH,
)
0.13
" In conscious normotensive rats, the hypotensive response to UR-8225 (1 mg/kg) did not diminish with repeated dosing for 16 days."( Cardiovascular effects of the novel potassium channel opener UR-8225.
Cavalcanti, F; Delpón, E; García-Rafanell, J; Gómez, L; Pérez, O; Tamargo, J, 1995
)
0.29
" Dose-response curves to PGE2, PGD2, and iloprost, a PGI2 analogue, were performed before and during KATP channel blockade with glibenclamide."( Evidence that prostaglandins I2, E2, and D2 may activate ATP sensitive potassium channels in the isolated rat heart.
Bouchard, JF; Dumont, E; Lamontagne, D, 1994
)
0.29
" Bladder activity and selectivity after oral dosing were studied in conscious, normotensive rats and dogs by monitoring cystometric and cardiovascular (CV) parameters."( ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.
Do, ML; Empfield, JR; Halterman, TJ; Howe, BB; Ohnmacht, CJ; Pettinger, SJ; Russell, K; Stow, RB; Trainor, DA; Yochim, CL, 1995
)
0.29
" In a 4-week chronic dosing study in SHR, TCV-295 (0."( Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs.
Awane, Y; Fujiwara, S; Hashiguchi, S; Kitayoshi, T; Kusumoto, K; Shiraishi, M; Terashita, Z; Watanabe, T, 1994
)
0.29
" The dose-response curve of the effects of levcromakalim on coronary perfusion pressure was shifted to the right in the presence of 20 nM to 1 microM glibenclamide."( The sensitivity of coronary vascular tone to glibenclamide: a study on the isolated perfused guinea pig heart.
Cyrys, S; Daut, J, 1994
)
0.55
" To test this hypothesis, we determined the dose-response relation to lemakalim, a selective activator of KATP channels, in isolated endothelium-denuded segments of the second (2B, internal diameter approximately 200 microns) and fourth (4B, internal diameter approximately 125 microns) branches of middle cerebral arteries taken from newborn (3-7 d old) and adult sheep."( Maturation enhances the sensitivity of ovine cerebral arteries to the ATP-sensitive potassium channel activator lemakalim.
Elliott, SR; Pearce, WJ, 1994
)
0.29
"1 ml), and dose-response curves to levcromakalim (a KATP channel opener) or isoproterenol were constructed."( Role of potassium channels in hypoxic relaxation of porcine bronchi in vitro.
Croxton, TL; Fernandes, LB; Hirshman, CA; Lindeman, KS, 1994
)
0.56
" The dose-response relation between ATP and the UDP-induced KATP-channel activity was shifted to the right in the presence of Mg2+ (2 mM)."( Regulation of ATP-sensitive K+ channels by ATP and nucleotide diphosphate in rabbit portal vein.
Kamouchi, M; Kitamura, K, 1994
)
0.29
" The slopes of the dose-response curves for noradrenaline, phenylephrine and methoxamine and frequency-response curves for renal nerve stimulation generated at each dose level of BRL38227 could not be distinguished statistically."( Effect of BRL 38227 on the adrenergic regulation of the kidney vasculature of the rat.
Johns, EJ, 1993
)
0.29
" Dose-response curves induced by bolus injection (i."( Effects of a K+ATP channel opener, lemakalim, on systemic, coronary and regional vascular dynamics in conscious dogs: comparison with nifedipine, adenosine, nitroglycerin and acetylcholine.
Shen, YT; Vatner, SF, 1993
)
0.29
" In SHR cells, the maximal slope conductance of the levcromakalim-evoked current, normalized by cell capacitance, was decreased, and the dose-response curve was shifted to the right compared with WKY cells."( Impaired action of levcromakalim on ATP-sensitive K+ channels in mesenteric artery cells from spontaneously hypertensive rats.
Abe, I; Fujii, K; Fujishima, M; Nagao, T; Ohya, Y; Setoguchi, M, 1996
)
0.86
"05) rightward shift of the dose-response curve for the depressor effects of adenosine (ED50 = 13."( The involvement of ATP-sensitive potassium channels and adenosine in the regulation of coronary flow in the isolated perfused rat heart.
Randall, MD, 1995
)
0.29
" Glibenclamide (30 microM) had no significant effect on relaxation of the dose-response curve to nitroglycerin and almost completely abolished the relaxation by cromakalim, a known opener of ATP-sensitive potassium channels."( Effect of selective inhibition of potassium channels on vasorelaxing response to cromakalim, nitroglycerin and nitric oxide of canine coronary arteries.
Hohn, J; Papp, JG; Pataricza, J; Penke, B; Toth, GK, 1995
)
0.71
"]) did not change tail-flick latency in control animals but produced a dose-dependent enhancement of the antinociception induced by clonidine and morphine, and shifted their dose-response curves to the left."( Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma-aminobutyric acid(B), mu and kappa opioid receptors.
Baeyens, JM; Barrios, M; Ocaña, M, 1996
)
1.74
" Isometric tension was measured and dose-response curves were constructed for levcromakalim (a KATP opener), Y-26763 (another KATP opener), isoprenaline and theophylline in guinea-pig isolated trachea that was challenged with ovalbumin or pretreated in vitro with either isoprenaline or the KATP openers."( Allergic responses reduce the relaxant effect of beta-agonists but not potassium channel openers in guinea-pig isolated trachea.
Dobashi, K; Houjou, S; Iizuka, K; Nakazawa, T, 1996
)
0.52
"Studies were undertaken to establish the regional hemodynamic profile and dose-response relation of the adenosine triphosphate (ATP)-dependent potassium channel activator lemakalim in anesthetized rats."( Regional hemodynamic dose-response of lemakalim and glybenclamide in anesthetized rats.
Cox, BF; Perrone, MH; Smits, GJ, 1997
)
0.3
" After preconstriction with the thromboxane analog, U46619 (9,11-dideoxy-11 alpha, 9 alpha-epoxymethano-prostaglandin F2 alpha), the pulmonary vascular dose-response relationship for the k+ATP agonist lemakalim was assessed in the conscious and halothane-anesthetized states and also in the conscious and enflurane-anesthetized states."( Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate-sensitive potassium channels compared to the conscious state.
Murray, PA; Nakayama, M; Sato, K; Seki, S, 1997
)
0.3
"05) in the lemakalim dose-response relationship."( Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate-sensitive potassium channels compared to the conscious state.
Murray, PA; Nakayama, M; Sato, K; Seki, S, 1997
)
0.3
" When dosed orally JTV-506 (0."( Effect of JTV-506, a novel vasodilator, on coronary blood flow in conscious dogs.
Aisaka, K; Hirata, Y, 1997
)
0.3
" No tolerance to the antihypertensive effect of KRN4884 was observed during a 15-day repeated dosing period."( KRN4884, a novel K channel opener: antihypertensive effects in conscious renal hypertensive dogs.
Endo, M; Izawa, T; Izumi, H; Jinno, Y; Kawahara, J; Takeuchi, A, 1997
)
0.3
" The specimens were precontracted with norepinephrine (1 microM) and a dose-response curve was established by adding cumulatively either sodium nitroprusside (n = 7), cromokalin (n = 7), or hydralazine (n = 7) at increasing concentrations."( Drug-induced vasodilation: the effects of sodium nitroprusside, hydralazine, and cromakalin on the rabbit carotid artery: in vitro and in vivo study.
Cromeens, D; Evans, GR; Gherardini, G; Gürlek, A; Joly, GA; Wang, B, 1997
)
0.3
" Lemakalim dose-response curves were also generated in rings pretreated with the nitric oxide synthase inhibitor, Nw-nitro-L-arginine methyl ester (L-NAME); the cyclooxygenase inhibitor, indomethacin; or the K+(ATP) channel antagonist, glybenclamide."( Halothane attenuates endothelium-dependent pulmonary vasorelaxant response to lemakalim, an adenosine triphosphate (ATP)-sensitive potassium channel agonist.
Horibe, M; Murray, PA; Seki, S, 1997
)
0.3
" The EC50 values for the dose-response curves established for the inhibition of histamine-induced contractions by adenosine were nearly identical to those obtained for the relaxations of fluoride-induced contractions by cromakalim: resp."( Role of adenosine-triphosphate-sensitive potassium channels in the mechanical responses of agonist-stimulated isolated porcine coronary arteries.
Nguyen, DH, 1997
)
0.48
" The bell-shaped dose-response relationship for ZD6169 activation of I(K(ATP)) has also been seen in bladder myocytes, albeit at a lower concentration, and it has been proposed to contribute to the reported lack of in vivo cardiovascular side effects."( The effects of ZD6169 on the ATP-dependent K(+) current (I(K)(ATP)) in isolated cat ventricular myocytes.
Jow, B; Numann, R, 1999
)
0.3
" Dose-response curves to the PGI2 analogue iloprost on phenylephrine-preconstricted rings of diabetic rats and controls were comparable."( Modification of vasodilator response in streptozotocin-induced diabetic rat.
Bouchard, JF; Dumont, EC; Lamontagne, D, 1999
)
0.3
" Diazoxide (2 microg/mouse) shifted morphine's dose-response curve 47-fold, while levcromakalim (0."( ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
Lohmann, AB; Welch, SP, 1999
)
0.53
" In isolated pulmonary arterial rings, 4-AP increased resting tension and caused a leftward shift in the KCl dose-response curve."( K(+) channel inhibition, calcium signaling, and vasomotor tone in canine pulmonary artery smooth muscle.
Damron, DS; Doi, S; Horibe, M; Murray, PA; Ogawa, K; Tanaka, S, 2000
)
0.31
"5 x 10(-6)) to generate two cumulative dose-response curves (CDRC I and II)."( Endothelium-dependent desensitization to angiotensin II in rabbit aorta: the mechanisms involved.
Coviello, A; de Bruno, MP; Jerez, S, 2001
)
0.31
" Bell-shaped dose-response curves were observed for these compounds and cromakalim indicating a downturn in response when a certain dose was exceeded."( Dualistic actions of cromakalim and new potent 2H-1,4-benzoxazine derivatives on the native skeletal muscle K ATP channel.
Antonio, L; Barbieri, M; Camerino, DC; Loiodice, F; Tortorella, P; Tricarico, D, 2003
)
0.87
" Infusion of the NO synthase blocker L-NMMA (100 microM) caused a rightward shift of the dose-response curve of vardenafil."( Vardenafil increases coronary flow response to hypercapnic acidosis in isolated guinea pig heart.
Brand, M; Deussen, A, 2007
)
0.34
"The effects of tramadol (racemic, R(-) and S(+): 10(-6), 10(-5), 5 x 10(-5) M), and glibenclamide on the levcromakalim dose-response curve were assessed in aortic rings that had been pre-contracted with phenylephrine."( Inhibitory effect of tramadol on vasorelaxation mediated by ATP-sensitive K+ channels in rat aorta.
Chang, KC; Cho, HC; Chung, YK; Lee, HK; Lee, JW; Park, KE; Shin, IW; Sohn, JT, 2007
)
0.55
" Levcromakalim produced concentration-dependent inhibitory effect on myometrial spontaneity and relaxant effect and the dose-response curve (DRC) was shifted towards right in the presence of glybenclamaide."( Cellular coupling of potassium channels with beta2 adrenoceptors in mediating myometrial relaxation in buffaloes (Bubalus bubalis).
Choudhury, S; Garg, SK; Mishra, SK; Singh, TU, 2010
)
0.92
") also did not affect log dose-response curves of prazosin, clonidine and Bay K 8644, a Ca(2+) channel activator, in normotensive rats."( Butylidenephthalide antagonizes cromakalim-induced systolic pressure reduction in conscious normotensive rats.
Chen, CM; Ko, WC; Lin, YJ; Shih, CH, 2015
)
0.7
" In general, the phosphate derivatives proved to be more chemically robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model."( Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity.
Dosa, PI; Fautsch, MP; Holman, BH; Roy Chowdhury, U; Stoltz, KL; Viker, KB, 2016
)
0.68
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1-benzopyran
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.12590.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency39.81070.00636.904339.8107AID883
lethal factor (plasmid)Bacillus anthracis str. A2012Potency31.62280.020010.786931.6228AID912
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency39.81070.00638.235039.8107AID883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 9Homo sapiens (human)IC50 (µMol)0.57000.22001.56004.3000AID78294
ATP synthase subunit beta, mitochondrialBos taurus (cattle)IC50 (µMol)100.00000.48000.48000.4800AID68758
ATP synthase subunit delta, mitochondrialBos taurus (cattle)IC50 (µMol)100.00000.48000.48000.4800AID68758
ATP synthase subunit gamma, mitochondrialBos taurus (cattle)IC50 (µMol)100.00000.48000.48000.4800AID68758
ATP synthase subunit epsilon, mitochondrialBos taurus (cattle)IC50 (µMol)100.00000.48000.48000.4800AID68758
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)100.00000.00031.38338.4000AID68758
ATP-binding cassette sub-family C member 8Homo sapiens (human)IC50 (µMol)0.57000.00431.07038.2000AID78294
ATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)IC50 (µMol)0.57000.00431.36868.2000AID78294
ATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)IC50 (µMol)0.57000.47000.88001.6000AID78294
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 9Homo sapiens (human)EC50 (µMol)0.28700.02190.70193.5400AID272328; AID272330; AID272331; AID93974; AID93975; AID93977; AID93978; AID93984
ATP-binding cassette sub-family C member 8Homo sapiens (human)EC50 (µMol)0.28040.02191.12578.8000AID93974; AID93975; AID93977; AID93978; AID93984
ATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)EC50 (µMol)0.28700.02190.97088.8000AID272328; AID272330; AID272331; AID93974; AID93975; AID93977; AID93978; AID93984
ATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)EC50 (µMol)0.28040.02190.54852.7542AID93974; AID93975; AID93977; AID93978; AID93984
ATP-binding cassette sub-family C member 9Homo sapiens (human)EC50 (µMol)0.64730.02190.70193.5400AID159672; AID347643; AID73908; AID80591
ATP-binding cassette sub-family C member 8Homo sapiens (human)EC50 (µMol)0.44640.02191.12578.8000AID159672; AID73908; AID80591
ATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)EC50 (µMol)0.44640.02190.97088.8000AID159672; AID73908; AID80591
ATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)EC50 (µMol)0.44640.02190.54852.7542AID159672; AID73908; AID80591
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (84)

Processvia Protein(s)Taxonomy
defense response to virusATP-binding cassette sub-family C member 9Homo sapiens (human)
action potentialATP-binding cassette sub-family C member 9Homo sapiens (human)
heart morphogenesisATP-binding cassette sub-family C member 9Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 9Homo sapiens (human)
response to ATPATP-binding cassette sub-family C member 9Homo sapiens (human)
negative regulation of blood pressureATP-binding cassette sub-family C member 9Homo sapiens (human)
fibroblast proliferationATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
coronary vasculature developmentATP-binding cassette sub-family C member 9Homo sapiens (human)
cardiac conductionATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
cardiac muscle cell contractionATP-binding cassette sub-family C member 9Homo sapiens (human)
monoatomic cation transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
intracellular glucose homeostasisATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
female pregnancyATP-binding cassette sub-family C member 8Homo sapiens (human)
memoryATP-binding cassette sub-family C member 8Homo sapiens (human)
visual learningATP-binding cassette sub-family C member 8Homo sapiens (human)
response to pHATP-binding cassette sub-family C member 8Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
response to zinc ionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of angiogenesisATP-binding cassette sub-family C member 8Homo sapiens (human)
response to lipopolysaccharideATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tumor necrosis factor productionATP-binding cassette sub-family C member 8Homo sapiens (human)
response to insulinATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of insulin secretionATP-binding cassette sub-family C member 8Homo sapiens (human)
neuromuscular processATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of glial cell proliferationATP-binding cassette sub-family C member 8Homo sapiens (human)
glutamate secretion, neurotransmissionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of neuroblast migrationATP-binding cassette sub-family C member 8Homo sapiens (human)
cellular response to organic substanceATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of uterine smooth muscle relaxationATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tight junction disassemblyATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of blood-brain barrier permeabilityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
action potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to hypoxiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ischemiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ventricular cardiac muscle tissue developmentATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glucose metabolic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
apoptotic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
determination of adult lifespanATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to xenobiotic stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to estradiolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ATPATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to testosteroneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
negative regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nervous system processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
CAMKK-AMPK signaling cascadeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to nicotineATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to glucose stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to tumor necrosis factorATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inorganic cation transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
positive regulation of protein localization to plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to resveratrolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion import across plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of monoatomic ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to hypoxiaATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
microglial cell activationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
kidney developmentATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of heart rateATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
adaptive immune responseATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to ischemiaATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
heart morphogenesisATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ventricular cardiac muscle tissue developmentATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
apoptotic processATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of blood pressureATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
determination of adult lifespanATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
protein secretionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to xenobiotic stimulusATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
gene expressionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
fatty acid transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
transmission of nerve impulseATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
establishment of cell polarityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to lipopolysaccharideATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to insulinATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to ATPATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to cytokineATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to endoplasmic reticulum stressATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
p38MAPK cascadeATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
vasodilationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to exogenous dsRNAATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
NLRP3 inflammasome complex assemblyATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
fat cell differentiationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
fibroblast proliferationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
neuromuscular processATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
synaptic assembly at neuromuscular junctionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
defense response to virusATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
atrioventricular node cell differentiationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
coronary vasculature developmentATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
glutamate secretion, neurotransmissionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
CAMKK-AMPK signaling cascadeATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
calcium ion transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
inorganic cation transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
reactive gliosisATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
transport across blood-brain barrierATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to resveratrolATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion import across plasma membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of monoatomic ion transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
defense response to virusATP-binding cassette sub-family C member 9Homo sapiens (human)
action potentialATP-binding cassette sub-family C member 9Homo sapiens (human)
heart morphogenesisATP-binding cassette sub-family C member 9Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 9Homo sapiens (human)
response to ATPATP-binding cassette sub-family C member 9Homo sapiens (human)
negative regulation of blood pressureATP-binding cassette sub-family C member 9Homo sapiens (human)
fibroblast proliferationATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
coronary vasculature developmentATP-binding cassette sub-family C member 9Homo sapiens (human)
cardiac conductionATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
cardiac muscle cell contractionATP-binding cassette sub-family C member 9Homo sapiens (human)
monoatomic cation transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 9Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
proton transmembrane transportATP synthase subunit beta, mitochondrialBos taurus (cattle)
proton transmembrane transportATP synthase subunit delta, mitochondrialBos taurus (cattle)
aerobic respirationATP synthase subunit delta, mitochondrialBos taurus (cattle)
mitochondrial proton-transporting ATP synthase complex assemblyATP synthase subunit delta, mitochondrialBos taurus (cattle)
proton transmembrane transportATP synthase subunit gamma, mitochondrialBos taurus (cattle)
proton transmembrane transportATP synthase subunit epsilon, mitochondrialBos taurus (cattle)
intracellular glucose homeostasisATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
female pregnancyATP-binding cassette sub-family C member 8Homo sapiens (human)
memoryATP-binding cassette sub-family C member 8Homo sapiens (human)
visual learningATP-binding cassette sub-family C member 8Homo sapiens (human)
response to pHATP-binding cassette sub-family C member 8Homo sapiens (human)
response to xenobiotic stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
response to zinc ionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of low-density lipoprotein particle clearanceATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of angiogenesisATP-binding cassette sub-family C member 8Homo sapiens (human)
response to lipopolysaccharideATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tumor necrosis factor productionATP-binding cassette sub-family C member 8Homo sapiens (human)
response to insulinATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of potassium ion transportATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of insulin secretionATP-binding cassette sub-family C member 8Homo sapiens (human)
neuromuscular processATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of glial cell proliferationATP-binding cassette sub-family C member 8Homo sapiens (human)
glutamate secretion, neurotransmissionATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of neuroblast migrationATP-binding cassette sub-family C member 8Homo sapiens (human)
cellular response to organic substanceATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
inorganic cation transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of uterine smooth muscle relaxationATP-binding cassette sub-family C member 8Homo sapiens (human)
positive regulation of tight junction disassemblyATP-binding cassette sub-family C member 8Homo sapiens (human)
negative regulation of blood-brain barrier permeabilityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion import across plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 8Homo sapiens (human)
action potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to hypoxiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ischemiaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ventricular cardiac muscle tissue developmentATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glucose metabolic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
apoptotic processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
determination of adult lifespanATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to xenobiotic stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to estradiolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to ATPATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to testosteroneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
negative regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of insulin secretionATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nervous system processATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
CAMKK-AMPK signaling cascadeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to nicotineATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to glucose stimulusATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cellular response to tumor necrosis factorATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inorganic cation transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
positive regulation of protein localization to plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to resveratrolATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion import across plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
regulation of monoatomic ion transmembrane transportATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
response to hypoxiaATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
microglial cell activationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
kidney developmentATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of heart rateATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
adaptive immune responseATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to ischemiaATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
heart morphogenesisATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ventricular cardiac muscle tissue developmentATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
apoptotic processATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of blood pressureATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
determination of adult lifespanATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
protein secretionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to xenobiotic stimulusATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
gene expressionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
fatty acid transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
transmission of nerve impulseATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
establishment of cell polarityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to lipopolysaccharideATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to insulinATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to ATPATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to cytokineATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to endoplasmic reticulum stressATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
p38MAPK cascadeATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
vasodilationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to exogenous dsRNAATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
NLRP3 inflammasome complex assemblyATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
fat cell differentiationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
fibroblast proliferationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
neuromuscular processATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
synaptic assembly at neuromuscular junctionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
defense response to virusATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
atrioventricular node cell differentiationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
coronary vasculature developmentATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
glutamate secretion, neurotransmissionATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
CAMKK-AMPK signaling cascadeATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
calcium ion transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
inorganic cation transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
reactive gliosisATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
transport across blood-brain barrierATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
response to resveratrolATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion import across plasma membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
regulation of monoatomic ion transmembrane transportATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (25)

Processvia Protein(s)Taxonomy
monoatomic cation channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 9Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium channel regulator activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 9Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ADP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
voltage-gated potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ankyrin bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
heat shock protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
transmembrane transporter bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
protein bindingATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ATP bindingATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
sulfonylurea receptor bindingATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
monoatomic cation channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 9Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium channel regulator activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 9Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 9Homo sapiens (human)
protein bindingATP synthase subunit beta, mitochondrialBos taurus (cattle)
ATP bindingATP synthase subunit beta, mitochondrialBos taurus (cattle)
ATP hydrolysis activityATP synthase subunit beta, mitochondrialBos taurus (cattle)
proton-transporting ATPase activity, rotational mechanismATP synthase subunit beta, mitochondrialBos taurus (cattle)
proton transmembrane transporter activityATP synthase subunit delta, mitochondrialBos taurus (cattle)
protein bindingATP synthase subunit gamma, mitochondrialBos taurus (cattle)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
sulfonylurea receptor activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ADP bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
transmembrane transporter bindingATP-binding cassette sub-family C member 8Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 8Homo sapiens (human)
voltage-gated potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
ankyrin bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
potassium ion bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
heat shock protein bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
transmembrane transporter bindingATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
protein bindingATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ATP bindingATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ATP-activated inward rectifier potassium channel activityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
sulfonylurea receptor bindingATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
ATPase-coupled monoatomic cation transmembrane transporter activityATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (24)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
sarcomereATP-binding cassette sub-family C member 9Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 9Homo sapiens (human)
membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 8Homo sapiens (human)
synaptic vesicle membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
sarcolemmaATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 8Homo sapiens (human)
membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
acrosomal vesicleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nuclear envelopeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
endosomeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inward rectifying potassium channelATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
intercalated discATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
T-tubuleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
axolemmaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
presynaptic membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
neuronal cell bodyATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cell body fiberATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glutamatergic synapseATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
myofibrilATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
sarcolemmaATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
presynaptic active zone membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
glutamatergic synapseATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
voltage-gated potassium channel complexATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
inward rectifying potassium channelATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion-transporting ATPase complexATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
sarcomereATP-binding cassette sub-family C member 9Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 9Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 9Homo sapiens (human)
membraneATP-binding cassette sub-family C member 9Homo sapiens (human)
mitochondrial proton-transporting ATP synthase complexATP synthase subunit beta, mitochondrialBos taurus (cattle)
mitochondrial envelopeATP synthase subunit delta, mitochondrialBos taurus (cattle)
mitochondrial proton-transporting ATP synthase complexATP synthase subunit delta, mitochondrialBos taurus (cattle)
proton-transporting ATP synthase complexATP synthase subunit delta, mitochondrialBos taurus (cattle)
mitochondrial proton-transporting ATP synthase complexATP synthase subunit gamma, mitochondrialBos taurus (cattle)
mitochondrial proton-transporting ATP synthase complex, catalytic sector F(1)ATP synthase subunit epsilon, mitochondrialBos taurus (cattle)
mitochondrial proton-transporting ATP synthase complexATP synthase subunit epsilon, mitochondrialBos taurus (cattle)
plasma membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
inward rectifying potassium channelATP-binding cassette sub-family C member 8Homo sapiens (human)
synaptic vesicle membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
sarcolemmaATP-binding cassette sub-family C member 8Homo sapiens (human)
potassium ion-transporting ATPase complexATP-binding cassette sub-family C member 8Homo sapiens (human)
membraneATP-binding cassette sub-family C member 8Homo sapiens (human)
acrosomal vesicleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
nuclear envelopeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
endosomeATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
inward rectifying potassium channelATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
intercalated discATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
T-tubuleATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
axolemmaATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
presynaptic membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
neuronal cell bodyATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
cell body fiberATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
glutamatergic synapseATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 11Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
myofibrilATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
sarcolemmaATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
presynaptic active zone membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
glutamatergic synapseATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
voltage-gated potassium channel complexATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
inward rectifying potassium channelATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
potassium ion-transporting ATPase complexATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
plasma membraneATP-sensitive inward rectifier potassium channel 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (197)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1351577Vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring assessed as reduction in 30 mM KCl-induced contraction after 15 mins in presence of 1 uM glibenclamide2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID272331Activity against pig bladder KATP channel opening assessed as ability to relax spontaneous bladder contraction2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
AID48985Binding affinity was determined by displacement of [3H]P1075 from its binding sites in canine cardiac membranes1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID159668Evaluated for change in mean arterial pressure from baseline at a plasma concentration of 44 nM in pigs2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID1626890Antiglaucoma activity in normotensive C57BL/6 mouse assessed as reduction in intraocular pressure at 5 mM administered topically as solution in mixture of DMSO, cremophor EL and PBS once daily as bolus dose to contralateral eye for 6 days followed by 5 mM2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity.
AID180316Inhibitory concentration against methoxamine-induced contractions in rat aorta1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID93975Evaluated for K-ATP activity in terms of membrane potential change, through guinea pig bladder assay2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of tricyclic dihydropyridine-based KATP openers that potently inhibit bladder contractions in vitro.
AID1626903Toxicity in normotensive C57BL/6 mouse assessed as effect on cell structure in aqueous humor outflow pathway at 5 mM administered topically as solution in mixture of DMSO, cremophor EL and PBS once daily as bolus dose to contralateral eye for 6 days by he2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity.
AID1351582Tracheorelaxant activity in Wistar rat trachea tonus assessed as reduction in 30 mM KCl-induced contraction after 15 mins2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID1351578Vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring assessed as reduction in 30 mM KCl-induced contraction after 15 mins in presence of 10 uM glibenclamide2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID175306Effective concentration required to increase time to the onset of contracture (TTC) in globally ischemic rat hearts1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID272346Activity against pig bladder KATP channel opening assessed as ability to relax field-stimulated pig detrusor relative to P10752006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
AID1626904Toxicity in normotensive C57BL/6 mouse assessed as effect on cell number in aqueous humor outflow pathway at 5 mM administered topically as solution in mixture of DMSO, cremophor EL and PBS once daily as bolus dose to contralateral eye for 6 days by hemat2016Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13
Analogs of the ATP-Sensitive Potassium (KATP) Channel Opener Cromakalim with in Vivo Ocular Hypotensive Activity.
AID159665Evaluated for change in mean arterial pressure from baseline at a plasma concentration of 12 nM in pigs2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID185883Antihypertensive effect after 1 mg/kg (po) administration in conscious spontaneously hypertensive rat (over a time period of 0-210 minutes).1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID93978K-ATP activity in terms of stable twitch response through field-stimulated landrace pig detrusor assay2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of tricyclic dihydropyridine-based KATP openers that potently inhibit bladder contractions in vitro.
AID232312EC25 and IC50 Ratio of the compound2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.
AID226482Hill Coefficient calculated by curve fitting of data to a single binding site model1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
Binding of ATP-sensitive potassium channel (KATP) openers to cardiac membranes: correlation of binding affinities with cardioprotective and smooth muscle relaxing potencies.
AID233874Selectivity expressed as the ratio of pEC50 (SLPD) and pEC50 (FSLPD)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID159666Evaluated for change in mean arterial pressure from baseline at a plasma concentration of 167 nM in pigs2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID180673The inhibitory concentration (IC50) for vasorelaxation on rat aorta2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.
AID175320The effective concentration (EC25) was measured for anti-ischemic activity on perfused rat hearts2001Journal of medicinal chemistry, May-24, Volume: 44, Issue:11
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress.
AID93974Evaluated for K-ATP activity in terms of change in membrane potential through guinea pig bladder assay2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID177042Dose required to reduce blood pressure by 30 mmHg after (po) administration in conscious spontaneously hypertensive rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID232391Ratio of ED30(20h) to ED30(2h) was determined1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID159567Evaluated for change in heart rate from baseline at a plasma concentration of 12 nM in pigs2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID159570Evaluated for change in heart rate from baseline at a plasma concentration of 44 nM in pigs2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID272328Ability to open human urinary bladder Kir6.2 channel containing SUR2B in Ltk cells by FLIPR assay2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
AID93977Evaluated for K-ATP activity in terms of stable twitch response through field-stimulated landrace pig detrusor assay2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID177044Dose required to reduce mean blood pressure after 2 hr following (po) administration conscious spontaneously hypertensive rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID1351580Ratio of EC50 for vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring in presence of 1 uM glibenclamide to EC50 for vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring in absence of glibenclamide2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID272347Activity against pig bladder KATP channel opening assessed as ability to relax spontaneous bladder contraction relative to P10752006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
AID272330Activity against pig bladder KATP channel opening assessed as ability to relax field-stimulated pig detrusor2006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
AID1351584Ratio of EC50 for Wistar rat trachea tonus to EC50 for Wistar rat endothelium-denuded thoracic aorta ring2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID159568Evaluated for change in heart rate from baseline at a plasma concentration of 167 nM in pigs2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID1351581Ratio of EC50 for vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring in presence of 10 uM glibenclamide to EC50 for vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring in absence of glibenclamide2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID177043Dose required to reduce mean blood pressure after 20 hr following (po) administration conscious spontaneously hypertensive rat1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.
AID1351575Vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring assessed as reduction in 30 mM KCl-induced contraction after 15 mins2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID1351579Vasorelaxing activity in Wistar rat endothelium-denuded thoracic aorta ring assessed as reduction in 80 mM KCl-induced contraction after 15 mins2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID1351583Tracheorelaxant activity in Wistar rat trachea tonus assessed as reduction in 30 mM KCl-induced contraction at 100 uM after 15 mins relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Design, synthesis and biological evaluation of novel ring-opened cromakalim analogues with relaxant effects on vascular and respiratory smooth muscles and as stimulators of elastin synthesis.
AID272329Ability to open human urinary bladder Kir6.2 containing SUR2B in Ltk cells by FLIPR assay relative to P10752006Journal of medicinal chemistry, Nov-16, Volume: 49, Issue:23
Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener.
AID93984Evaluated for K-ATP activity as in vitro bladder relaxation in spontaneous Landrace pig detrusor strips (SLPD)2004Journal of medicinal chemistry, Jun-03, Volume: 47, Issue:12
Synthesis and structure-activity relationships of a novel series of 2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide K(ATP) channel openers: discovery of (-)-(9S)-9-(3-bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)
AID366928Cardioprotective effect in Langendorff perfused Wistar rat hearts assessed as ratio for ischemic injured area to total area at 1 mg/kg, ip2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Enantioselectivity in cardioprotection induced by (S)- (-)-2,2-dimethyl-N-(4'-acetamido-benzyl)-4-spiromorpholone-chromane.
AID452150Channel opening activity at KATP channel in Wistar rat endothelium-denuded aortic ring assessed as relaxation of KCl-induced contraction2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID181484Systolic blood pressure at intervals from 1 to 6 hr in groups of six rats after 0.3 mg/kg p.o. administration.1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID1141750Ratio of EC50 for myorelaxant activity in endothelium-free rat thoracic aorta presence of 1 uM of KATP channel blocker glibenclamide to EC50 for myorelaxant activity in endothelium-free rat thoracic aorta absence of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID1454770Anti-hypertensive activity in conscious spontaneously hypertensive Okamoto rat assessed as reduction in systolic blood pressure at 0.1 mg/kg, po measured up to 6 hrs post dose relative to control2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID78139Inhibition of spontaneous tone in guinea pig isolated trachealis1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols.
AID159675Potassium channel opening activity compared to P1075 in isolated Landrace pig bladder strips2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs).
AID212401Compound was tested for relaxant activity in taenia caecum1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID185909Maximum fall in blood pressure was evaluated at an oral dose of 3.0 mg/kg in (SHR) spontaneous hypertensive rats1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans.
AID220539Compound was tested for the antihypertensive activity in dogs by intravenous injection at a dose of 30 ug/kg1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID230909Ratio of anti-ischemic potency and vasorelaxant potency in rat.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.
AID177207The compound was evaluated for hypotensive activity in anaesthetized Sprague Dawley rats on intravenous administration1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Synthesis and biological activity of trans(+-)-N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (RP 49356) and analogues: a new class of potassium channel opener.
AID384241Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion at 10 uM relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID247090Myorelaxant effect of the compound on 30 mM KCl induced rat aorta rings determined after incubated with the 0 uM glibenclamide in the medium; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID80591PEC50 for functional potassium channel opening activity in isolated bladder strips2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs).
AID389990Cardioprotective activity in Langendorff perfused Wistar rat assessed as rate pressure product at 1 mg/kg, ip recorded after 30 mins of global ischemia followed by 120 mins of reperfusion2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID1141748Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 30 mM of KCl-induced contraction in presence of 10 uM of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID253017Percentage of residual insulin secretion value in the pancreatic islets of rat after treatment with the compound at 10 uM concentration2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID68762Inhibitory concentration towards rat mitochondrial F1F0-ATP synthase using a hexokinase / glucose-6-phosphate dehydrogenase coupled assay2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.
AID159529Maximal efficacy was expressed in comparison to P1075 using KATP activity in pig bladder strips2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Structure-activity relationship of a novel class of naphthyl amide KATP channel openers.
AID384242Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion at 1 uM relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID194216Change in heart rate in beats per minute in anesthetized female rats at a dose of 0.30 mg/kg and a cumulative dose of 0.44 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID320895Vasorelaxation activity against phenylephrine-stimulated contraction in rat thoracic tissue at 10 uM2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
The synthesis and biological evaluation of a range of novel functionalized benzopyrans as potential potassium channel activators.
AID1712310Myorelaxant activity in aortic rings isolated from Wistar rat assessed as reduction in KCl-induced contractions measured after 60 mins in presence of 80 mM KCl by force-displacement transducer2016European journal of medicinal chemistry, Oct-04, Volume: 1214-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.
AID246968Myorelaxant effect of the compound on 80 mM KCl induced rat aorta rings determined; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID320894Vasorelaxation activity against phenylephrine-stimulated contraction in rat thoracic tissue at 1 uM2008Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3
The synthesis and biological evaluation of a range of novel functionalized benzopyrans as potential potassium channel activators.
AID233806Ratio of the EC25 value for time to contracture and IC50 value for vasorelaxant potency indicates selectivity in vitro for the ischemic myocardium.1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.
AID166913Compound measured for hyperpolarization of smooth muscle cells of the rabbit main pulmonary artery at concentration 3 uM.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID274638Decrease in systolic blood pressure in Wistar rat at 1 mg/kg, ip after 60 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID166322Increase in rubidium-86 efflux in rabbit isolated mesenteric artery over basal rate1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID384245Ratio of IC50 for glucose-induced insulin secretion in Wistar rat pancreatic beta islets to EC50 for myorelaxant activity in Wistar rat aorta rings2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID180699In vitro inhibitory concentration producing 90% reduction in maximum contraction produced by KCl (20 mmol) in isolated aorta of rat.1992Journal of medicinal chemistry, Oct-02, Volume: 35, Issue:20
Synthesis and biological activity of trans(+-)-N-methyl-2-(3-pyridyl)-2-tetrahydrothiopyrancarbothioamide 1-oxide (RP 49356) and analogues: a new class of potassium channel opener.
AID76593Inhibition of Histamine-induced bronchospasm was measured by measuring % prolongation of collapse time of guinea pig1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Relaxant activity of 6-cyano-2,2-dimethyl-2H-1-benzopyran-4-carboxamides and -thiocarboxamides and their analogues in guinea pig trachealis.
AID230962Ratio of the concentration increasing time to contracture by 25% (EC25) in rat heart and concentration showing vasorelaxant potency (IC50) in rat aorta.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Cardioselective anti-ischemic ATP-sensitive potassium channel openers. 3. Structure-activity studies on benzopyranyl cyanoguanidines: modification of the cyanoguanidine portion.
AID177045Dose required to reduce mean blood pressure by 30 mmHg in spontaneously hypertensive rats1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
4-Heterocyclyloxy-2H-1-benzopyran potassium channel activators.
AID171481Antihypertensive activity measured by maximum fall in the mean blood pressure after an oral administration of 1 mg/kg in spontaneously hypertensive rats1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
4-Heterocyclyloxy-2H-1-benzopyran potassium channel activators.
AID407860Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as glucose-induced residual insulin secretion at 10 uM relative to control2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID274630LDH release in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip after 120 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID194215Change in heart rate in beats per minute in anesthetized female rats at a dose of 0.10 mg/kg and a cumulative dose of 0.14 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID181703In vitro relaxation of rat aorta precontracted with methoxamine.1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
AID181491Systolic blood pressure was measured at intervals from 1 to 6 hr in groups of six rats after oral administration of a dose of 1.0 mg/kg1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID194656Oral antihypertensive activity in spontaneously hypertensive rats at a dose of 0.3 mg/kg (po)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and antihypertensive activity of 3-[(substituted-carbonyl)amino]-2H-1-benzopyrans.
AID165453Drug concentration required to induce half maximal hyperpolarization in rabbit main pulmonary arteries1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID452149Channel opening activity at KATP channel in Wistar rat pancreatic islets assessed as glucose-induced residual insulin secretion at 1 uM after 90 mins by radioimmunology2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID194389Change in mean arterial pressure in anesthetized female rats at a dose of 0.03 mg/kg and a cumulative dose of 0.04 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID194236In vivo activity was evaluated by measuring heart rate(HR) after 3 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID389992Cardioprotective activity in Langendorff perfused Wistar rat assessed as rate pressure product at 40 mg/kg, ip recorded after 30 mins of ischemia followed by 120 mins of reperfusion in presence of 5-hydroxydecanoic acid2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID194244In vivo activity was evaluated by measuring interval between bladder contractions (IC) after 3 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID194671The maximum fall in systolic blood pressure was determined at a dose of 0.1 mg/kg after oral administration in rats1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Variation in the aromatic ring of cromakalim: antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans.
AID274623Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip after 30 mins in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID78296Contraction and relaxation of guinea pig portal vein with KCl and glibenclamide respectively1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID389991Antiischemic activity in Langendorff perfused Wistar rat assessed as ratio of ischemic area to total area at 1 mg/kg, ip2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID175289Anti-ischemic potency determined as concentration required for increase in time to contracture in globally ischemic rat hearts1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cardioselective anti-ischemic ATP-sensitive potassium channel openers.
AID407861Activation of ATP-sensitive potassium channel in potassium-depolarized Wistar rat aortic rings assessed as myorelaxant activity against KCl-induced contraction2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID233947Ratio of Antiischemic potency to vasorelaxant potency.1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
AID77612Intrinsic activity measured on Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID76086Inhibition of spontaneous tone in guinea pig tracheal spirals1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Relaxant activity of 6-cyano-2,2-dimethyl-2H-1-benzopyran-4-carboxamides and -thiocarboxamides and their analogues in guinea pig trachealis.
AID77610Intrinsic activity was measured for inhibition of spontaneous tone in guinea pig isolated trachealis1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and smooth muscle relaxant activity of a new series of potassium channel activators: 3-amido-1,1-dimethylindan-2-ols.
AID195204Vasorelaxant potency was assessed by measurement of inhibition of methoxamine-contracted rat aorta1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.
AID195203Vasorelaxant potency determined by measurement of IC50 value for relaxation of rat aorta precontracted with methoxamine1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.
AID1141746Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 30 mM of KCl-induced contraction2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID1141751Ratio of EC50 for myorelaxant activity in endothelium-free rat thoracic aorta presence of 10 uM of KATP channel blocker glibenclamide to EC50 for myorelaxant activity in endothelium-free rat thoracic aorta absence of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID194213Change in heart rate in beats per minute in anesthetized female rats at a dose of 0.03 mg/kg and a cumulative dose of 0.04 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID1141747Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 30 mM of KCl-induced contraction in presence of 1 uM of KATP channel blocker glibenclamide2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID274626Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip after 120 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID181483Systolic blood pressure was measured at intervals from 1 to 6 hr in groups of six rats after oral administration of a dose of 0.1 mg/kg1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans.
AID194388Change in mean arterial pressure in anesthetized female rats at a dose of 0.01 mg/kg and a cumulative dose of 0.01 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID389996Hypotensive activity in normotensive Wistar rat assessed as systolic blood pressure at 1 mg/kg, ip after 90 mins2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID347646Channel opening activity at SUR2A/Kir6.2 potassium ATP channel in african green monkey COS7 cells assessed as isometric force by FLIPR2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID1454768Anti-hypertensive activity in conscious spontaneously hypertensive Okamoto rat assessed as reduction in systolic blood pressure at 0.3 mg/kg, po measured up to 6 hrs post dose relative to control2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID1454769Anti-hypertensive activity in conscious spontaneously hypertensive Okamoto rat assessed as reduction in systolic blood pressure at 1 mg/kg, po measured up to 6 hrs post dose relative to control2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID228165Vasorelaxant activity expressed as negative logarithm of the concentration causing a 50% inhibition of spontaneous myogenic activity in rat portal vein.1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID389993Vasorelaxation activity in Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction at 100 uM relative to KCl2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID347648Selectivity ratio of EC50 for african green monkey SUR2A/Kir6.2 potassium ATP channel to human SUR2B/Kir6.2 potassium ATP channel2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID389994Vasorelaxation activity in Wistar rat thoracic aortic ring assessed as inhibition of KCl-induced contraction2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Spirocyclic benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel.
AID437030Cardioprotective effect in Langendorff perfused isolated rat hearts assessed as reduction in ischemic injury2009Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15
Predictive models, based on classification algorithms, for compounds potentially active as mitochondrial ATP-sensitive potassium channel openers.
AID78294IC50 evaluated by measuring contraction and relaxation of guinea pig bladder strips with KCl and glibenclamide respectively1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID194658Oral antihypertensive activity in spontaneously hypertensive rats at a dose of 1 mg/kg (po)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and antihypertensive activity of 3-[(substituted-carbonyl)amino]-2H-1-benzopyrans.
AID247094Myorelaxant effect of the compound on 30 mM KCl induced rat aorta rings determined after incubated with the 10 uM glibenclamide in the medium; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID194391Change in mean arterial pressure in anesthetized female rats at a dose of 0.10 mg/kg and a cumulative dose of 0.14 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID194665The compound was tested for the maximum fall in systolic blood pressure 1-6 hr of 0.3 mg/kg oral dose administration in rats1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and antihypertensive activity of pyran oxygen and amide nitrogen replacement analogues of the potassium channel activator cromakalim.
AID268575Residual insulin release in Wistar rat pancreatic islet beta cells in presence of glucose at 10 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.
AID77602Evaluated by measuring inhibition of spontaneous tone in guinea pig tracheal spirals1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Relaxant activity of 6-cyano-2,2-dimethyl-2H-1-benzopyran-4-carboxamides and -thiocarboxamides and their analogues in guinea pig trachealis.
AID1141749Myorelaxant activity in endothelium-free rat thoracic aorta assessed as inhibition of 80 mM of KCl-induced contraction2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID194392Change in mean arterial pressure in anesthetized female rats at a dose of 0.30 mg/kg and a cumulative dose of 0.44 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID185904Maximum fall in blood pressure was evaluated at an oral dose of 0.1 mg/kg in (SHR) spontaneous hypertensive rats1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans.
AID194243In vivo activity was evaluated by measuring interval between bladder contractions (IC) after 1 hours1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID68758Inhibitory concentration towards rat mitochondrial F1F0 ATP hydrolase using a pyruvate kinase / lactate dehydrogenase system2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Small molecule mitochondrial F1F0 ATPase hydrolase inhibitors as cardioprotective agents. Identification of 4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors.
AID268578Inhibition of insulin release in Wistar rat pancreatic islet beta cells2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.
AID347647Selectivity ratio of EC50 for mouse SUR1/Kir6.2 potassium ATP channel to human SUR2B/Kir6.2 potassium ATP channel2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID194396In vivo activity was evaluated by measuring mean arterial pressure(MAP) after 5 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID194672The maximum fall in systolic blood pressure was determined at a dose of 0.3 mg/kg after oral administration in rats1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Variation in the aromatic ring of cromakalim: antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans.
AID268579Selectivity ratio, IC50 for Wistar rat pancreatic islet beta cells/EC50 for aortic rings2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.
AID185905Maximum fall in blood pressure was evaluated at an oral dose of 0.3 mg/kg in (SHR) spontaneous hypertensive rats1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans.
AID9782Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID274631LDH release in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip after 120 mins in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID407859Activation of ATP-sensitive potassium channel in Wistar rat pancreatic beta islets assessed as glucose-induced residual insulin secretion at 50 uM relative to control2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID268576Myorelaxant activity against KCL-induced contraction of Wistar rat aortic rings2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.
AID274635Ischemia-injured area relative to total area in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID194394In vivo activity was evaluated by measuring mean arterial pressure(MAP) after 1 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID196895Concentration necessary for increase in time to contracture by 25% in the globally ischemic rat hearts1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Cardioselective anti-ischemic ATP-sensitive potassium channel openers. 3. Structure-activity studies on benzopyranyl cyanoguanidines: modification of the cyanoguanidine portion.
AID347645Channel opening activity at SUR1/Kir6.2 potassium ATP channel in mouse beta-TC6 cells assessed as isometric force by FLIPR2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID194245In vivo activity was evaluated by measuring interval between bladder contractions (IC) after 5 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID159418In vitro concentration to suppress electrically stimulated contraction in isolated Landrance pig bladder detrusor strips2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The discovery of a new class of large-conductance Ca2+-activated K+ channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles.
AID247091Myorelaxant effect of the compound on 30 mM KCl induced rat aorta rings determined after incubated with the 1 uM glibenclamide in the medium; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID452148Channel opening activity at KATP channel in Wistar rat pancreatic islets assessed as glucose-induced residual insulin secretion at 10 uM after 90 mins by radioimmunology2009Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
New R/S-3,4-dihydro-2,2-dimethyl-2H-1-benzopyrans as K(ATP) channel openers: modulation of the 4-position.
AID161275Binding affinity towards potassium channel of rat aorta using [3H]15 as radioligand1993Journal of medicinal chemistry, Jul-09, Volume: 36, Issue:14
Synthesis of and radioligand binding studies with a tritiated pinacidil analogue: receptor interactions of structurally different classes of potassium channel openers and blockers.
AID159426In vitro maximal efficacy in stable twitch response in isolated Landrace pig bladder detrusor strips relative to P-10752003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
The discovery of a new class of large-conductance Ca2+-activated K+ channel opener targeted for overactive bladder: synthesis and structure-activity relationships of 2-amino-4-azaindoles.
AID179236Compound was tested for vasorelaxant activity on the basis of ability to relax endothelium-denuded rat aortic strips toned with 20 mM KCl1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID407862Ratio of IC50 for inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets to ED50 for myorelaxant activity in Wistar rat aortic rings2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and activity on rat aorta rings and rat pancreatic beta-cells of ring-opened analogues of benzopyran-type potassium channel activators.
AID274637Vasorelaxation activity on KCl-induced contractile tone in Wistar rat thoracic aortic ring at 100 uM2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID274636Vasorelaxation activity on KCl-induced contractile tone in Wistar rat thoracic aortic ring2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID194212Change in heart rate in beats per minute in anesthetized female rats at a dose of 0.01 mg/kg and a cumulative dose of 0.01 mg/kg1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID9781Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
AID1712308Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic islets at 1 uM incubated for 90 mins in presence of 16.7 mM glucose by radioimmunological assay relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 1214-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.
AID73908Potassium channel opening activity determined in cultured guinea pig urinary bladder cells2002Bioorganic & medicinal chemistry letters, Jun-03, Volume: 12, Issue:11
Structure-Activity studies for a novel series of tricyclic dihydropyrimidines as K(ATP) channel openers (KCOs).
AID274627Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip after 120 mins in presence of 5-hydroxydecanoic acid2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID175292Antiischemic potency by measurement of increase in time to contracture in globally ischemic isolated perfused rat hearts1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Cardioselective antiischemic ATP-sensitive potassium channel (K(ATP)) openers. 6. Effect of modifications at C6 of benzopyranyl cyanoguanidines.
AID247873Inhibitory concentration against rat vascular smooth muscle tissue2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID222118Compound was tested for relaxant activity in trachea for asthma in male guinea pigs1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID274622Activity in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip after 30 mins2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID76393Inhibition of spontaneous tone in Guinea pig tracheal spiral strips.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Relaxant activity of 4-amido-3,4-dihydro-2H-1-benzopyran-3-ols and 4-amido-2H-1-benzopyrans on guinea pig isolated trachealis.
AID396087Inhibition of SUR2A/kir6.2 channel in Wistar rat thoracic aorta assessed as relaxation of Kcl-induced contraction2008European journal of medicinal chemistry, Nov, Volume: 43, Issue:11
QSAR study about ATP-sensitive potassium channel activation of cromakalim analogues using CP-MLR approach.
AID194395In vivo activity was evaluated by measuring mean arterial pressure(MAP) after 3 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID196896In vitro anti-ischemic potency was determined by measurement of concentration necessary for increase in time to contracture by 25% in the globally ischemic rat hearts1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Cardioselective antiischemic ATP-sensitive potassium channel openers. 2. Structure-activity studies on benzopyranylcyanoguanidines: modification of the benzopyran ring.
AID180680Vasorelaxant potency determined by inhibition of methoxamine-contracted rat aorta1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cardioselective anti-ischemic ATP-sensitive potassium channel openers.
AID194235In vivo activity was evaluated by measuring heart rate(HR) after 1 hour.1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID1454771Anti-hypertensive activity in conscious spontaneously hypertensive Okamoto rat assessed as reduction in systolic blood pressure at 3 mg/kg, po measured up to 6 hrs post dose relative to control2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
Natural-Products-Inspired Use of the gem-Dimethyl Group in Medicinal Chemistry.
AID222119Compound was tested for relaxant activity in urinary bladder for urinary incontinence in male guinea pigs1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Biologically selective potassium channel openers having 1,1-diethylpropyl group.
AID194674The maximum fall in systolic blood pressure was determined at a dose of 1.0 mg/kg after oral administration in rats1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Variation in the aromatic ring of cromakalim: antihypertensive activity of pyranopyridines and 6-alkyl-2H-1-benzopyrans.
AID384243Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic beta islets assessed as residual insulin secretion relative to control2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID177180Effective dose (after peroral administration) required to decrease systolic blood pressure by 30 mmHg in spontaneously hypertensive rats (SHR)1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
2,2-Dialkylnaphthalen-1-ones as new potassium channel activators.
AID165454Relaxing effect by measuring inhibition of noradrenaline-induced contractions in rabbit main pulmonary arteries1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID195202Tested for the vasorelaxant potency in methoxamine contracted rat aorta1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Cardioselective anti-ischemic ATP-sensitive potassium channel openers. 3. Structure-activity studies on benzopyranyl cyanoguanidines: modification of the cyanoguanidine portion.
AID231462Ratio between EC25 and EC50 values was determined1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Cardioselective anti-ischemic ATP-sensitive potassium channel openers.
AID196894Antiischemic potency is determined by EC25 value for increase in time to the onset of contracture in globally ischemic isolated perfused rat hearts.1997Journal of medicinal chemistry, Jan-03, Volume: 40, Issue:1
Cardioselective antiischemic ATP-sensitive potassium channel (KATP) openers. 5. Identification of 4-(N-aryl)-substituted benzopyran derivatives with high selectivity.
AID366926Cardioprotective effect in Langendorff perfused Wistar rat hearts assessed as ischemic damage measured by rate-pressure product-120 at 1 mg/kg, ip2009Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5
Enantioselectivity in cardioprotection induced by (S)- (-)-2,2-dimethyl-N-(4'-acetamido-benzyl)-4-spiromorpholone-chromane.
AID159676Relaxing effect determined by measuring inhibition of acetylcholine-induced contractions in pig coronary arteries.1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
3-Methyl-2H-1-benzopyran potassium channel activators.
AID194655Compound was evaluated for oral antihypertensive activity in spontaneously hypertensive rats at a dose of 0.1 mg/kg (po)1992Journal of medicinal chemistry, May-01, Volume: 35, Issue:9
Synthesis and antihypertensive activity of 3-[(substituted-carbonyl)amino]-2H-1-benzopyrans.
AID347643Channel opening activity at SUR2B/Kir6.2 potassium ATP channel in human TE671 cells assessed as isometric force by FLIPR2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Discovery and structure-activity relationships of a novel series of benzopyran-based K(ATP) openers for urge urinary incontinence.
AID194666The compound was tested for the maximum fall in systolic blood pressure 1-6 hr of 1.0 mg/kg oral dose administration in rats1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Synthesis and antihypertensive activity of pyran oxygen and amide nitrogen replacement analogues of the potassium channel activator cromakalim.
AID274634Ischemia-injured area relative to total area in Langendorff perfused Wistar rat heart subjected to ischemia-reperfusion cycles at 1 mg/kg, ip2006Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26
New benzopyran-based openers of the mitochondrial ATP-sensitive potassium channel with potent anti-ischemic properties.
AID159672Potent effective concentration was evaluated for KATP channel opening activity in pig bladder strips2003Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10
Structure-activity relationship of a novel class of naphthyl amide KATP channel openers.
AID1712309Inhibition of glucose-induced insulin secretion in Wistar rat pancreatic islets at 10 uM incubated for 90 mins in presence of 16.7 mM glucose by radioimmunological assay relative to control2016European journal of medicinal chemistry, Oct-04, Volume: 1214-Phenylureido/thioureido-substituted 2,2-dimethylchroman analogs of cromakalim bearing a bulky 'carbamate' moiety at the 6-position as potent inhibitors of glucose-sensitive insulin secretion.
AID268577Residual insulin release in Wistar rat pancreatic islet beta cells in presence of glucose at 1 uM2006Journal of medicinal chemistry, Jul-27, Volume: 49, Issue:15
Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.
AID15881The calculated Octanol/Water partition coefficient CLogP1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID247010Myorelaxant activity of the compound against insulin secretion in the pancreatic islets ofrat; (activity expressed as ED50)2005Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2
4,6-Disubstituted 2,2-dimethylchromans structurally related to the K(ATP) channel opener cromakalim: design, synthesis, and effect on insulin release and vascular tone.
AID194238In vivo activity was evaluated by measuring heart rate(HR) after 5 hours1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.
AID177031Compound was tested for hypotensive activity in anesthetized normotensive rats by intravenous injection. Systolic blood pressure measured 30 min after injection1994Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13
Novel potassium-channel openers: preparation and pharmacological evaluation of racemic and optically active N-(6-amino-3-pyridyl)-N'-bicycloalkyl-N"-cyanoguanidine derivatives.
AID384244Myorelaxant activity in potassium depolarized Wistar rat aorta rings assessed as relaxation of KCl-induced contraction2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
New R/S-3,4-dihydro-2,2-dimethyl-6-halo-4-(phenylaminothiocarbonylamino)-2H-1-benzopyrans structurally related to (+/-)-cromakalim as tissue-selective pancreatic beta-cell K(ATP) channel openers.
AID1141745Inhibition of glucose-induced insulin secretion in rat pancreatic islets assessed as residual insulin release level at 10 uM preincubated for 30 mins measured after 90 mins radioimmunology analysis2014European journal of medicinal chemistry, Jun-10, Volume: 80Influence of the alkylsulfonylamino substituent located at the 6-position of 2,2-dimethylchromans structurally related to cromakalim: from potassium channel openers to calcium entry blockers?
AID1346659Mouse Kv1.7 (Voltage-gated potassium channels)1998The Journal of biological chemistry, Mar-06, Volume: 273, Issue:10
Genomic organization, chromosomal localization, tissue distribution, and biophysical characterization of a novel mammalian Shaker-related voltage-gated potassium channel, Kv1.7.
AID1346681Mouse Kv3.1 (Voltage-gated potassium channels)1994Molecular pharmacology, Jun, Volume: 45, Issue:6
Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
AID1346573Mouse Kir6.2 (Inwardly rectifying potassium channels)1996Neuron, May, Volume: 16, Issue:5
A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,381)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990105 (7.60)18.7374
1990's923 (66.84)18.2507
2000's264 (19.12)29.6817
2010's71 (5.14)24.3611
2020's18 (1.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.66 (24.57)
Research Supply Index7.25 (2.92)
Research Growth Index5.28 (4.65)
Search Engine Demand Index48.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (1.44%)5.53%
Trials0 (0.00%)5.53%
Reviews34 (2.45%)6.00%
Reviews1 (2.27%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,334 (96.11%)84.16%
Other43 (97.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Study of Local Physiological Effects Following Intradermal and Intramuscular Injection of Levcromacalim [NCT03726242]20 participants (Actual)Interventional2018-11-01Completed
Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine: A Randomized Double-Blind Two-Way Crossover Study [NCT05211050]20 participants (Anticipated)Interventional2022-02-15Recruiting
Effect of Levcromakalim in Individuals With Migraine Pretreated With Erenumab: A Randomized Double-Blind Placebo-Controlled Two-Way Crossover Trial [NCT05889442]16 participants (Actual)Interventional2023-03-09Completed
Headache Inducing Effect of Levcromakalim in Migraine With Aura Patients [NCT04012047]17 participants (Actual)Interventional2019-07-09Completed
Migraine Inducing Effect of Levcromakalim in Patients With Migraine With Aura [NCT04905654]35 participants (Actual)Interventional2021-09-29Completed
Structural and Functional Cerebral Changes After Infusion of ATP Sensitive Potassium Channel Opener Levcromakalim. [NCT05565001]20 participants (Anticipated)Interventional2022-09-01Recruiting
The Hemodynamics Effect of Levcromakalim After Glibenclamide Administration Assessed by High Resolution MRA Technique in a Randomized, Double-blind, Cross-over and Placebo-controlled Study With Healthy Volunteers. [NCT03886922]15 participants (Anticipated)Interventional2019-04-01Recruiting
The Headache-inducing Effects of Levcromakalim in Patients With Cluster Headache [NCT05093582]41 participants (Actual)Interventional2021-06-04Completed
The Effect of Levcromakalim Infusion on the Cranial Arteries Over Several Hours Using a High Resolution MRA Technique in a Randomized, Double-blind Placebo-controlled Design in Healthy Volunteers. [NCT03609008]20 participants (Actual)Interventional2018-06-26Completed
Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache: A Randomized Clinical Trial [NCT05243953]21 participants (Actual)Interventional2022-03-21Completed
The Effects of Levcromakalim on Cerebral Hemodynamic in Migraine Patients [NCT03228355]16 participants (Actual)Interventional2017-05-24Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]